 The U.K.s National Institute for Health and Care Excellence NICE has recommended BioCryst Pharmaceuticals Incs NASDAQ: BCRX Orladeyo berotralstat for hereditary angioedema HAE. The recommendation covers eligible patients 12 years and older if they have at least two attacks per month. 